Physician profile
Richie Lin
NPI 1417120932
$5,362.54
in general payments reported to CMS, 2019-2025
33 companies · $713 in 2025
The $713 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $489 · 2021: $678 · 2022: $1,398 · 2023: $549 · 2024: $854 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.55 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,201.28 | 2019-2025 | |
| Janssen Biotech, INC. | $959.22 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $359.65 | 2019-2025 | |
| Lilly USA, LLC | $341.95 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $294.78 | 2019-2024 | Odomzo, Blu-U, Winlevi |
| Allergan, INC. | $257.95 | 2019-2022 | |
| Amgen INC. | $244.53 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $216.79 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $155.17 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $154.45 | 2019-2024 | |
| Galderma Laboratories, L.P. | $152.29 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $136.78 | 2019-2020 | |
| Genzyme Corporation | $125.25 | 2020-2022 | |
| Boston Scientific Corporation | $105.93 | 2025 | Eluvia |
| Journey Medical Corporation | $102.34 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $74.49 | 2019 | |
| Celgene Corporation | $59.53 | 2019-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $59.52 | 2020-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $56.22 | 2020-2022 | |
| Biofrontera INC. | $38.61 | 2019-2022 | |
| Almirall LLC | $31.21 | 2019-2025 | Klisyri |
| Ucb, INC. | $30.73 | 2021-2025 | Bimzelx |
| Dermira, INC. | $29.47 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $28.17 | 2023-2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $26.58 | 2025 | Sotyktu |
| Dermavant Sciences, INC. | $17.20 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $15.70 | 2024 | Zoryve |
| Mission Pharmacal Company | $15.02 | 2021 | |
| Nabriva Therapeutics, Plc | $15.00 | 2022 | |
| Botanix Sb INC | $14.40 | 2025 | Sofdra |
| Mylan Pharmaceuticals INC. | $14.23 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.07 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.03 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richie Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.